From ONC's Management Discussion...https://www.sedar.com/csfsprod/data52/filings/00746233/00000001/s%3A%5CC4%5C922%5C000850%5C00922%5CSEDAR%5COncoBio%5C2005%5CMD%26A.pdf
go to Results of Operations
Under Clinical Trial Program, it shows the following amounts
2004 - $799,990
2003 - $130,034
2002 - $504,260
Under Pre-Clinical Trials & Research Collaborations, oncy spent the following amounts
2004 - $824,889
2003 - $322,060
2002 - $663,012
Under Operating Expenses, onc spent the following amounts in relation to Public Company Expenses
2004 - $1,910,611
2003 - $1,633,849
2002 - $1,374,172
so in 2004, onc spent over 10% more on investor relations than on clinical & pre-clinical trials
in 2003, onc spent almost 4 TIMES as much on investor relations than clinical & pre-clinical trials (thats the year they had 3 separate financings, 4 inclding the one that closed Dec/02)
in 2002, onc spent about 20% more on investor relations than on clinical & pre-clinical trials.
and before anyone suggests the "legal" fees under "investor relations" relate to patent costs, you need to read the Capitalization and Amortization of Patent Costs section. i guess the AGMs must cost a bundle lol
these guys are spending significantly more time and money on investor relations than on clinical trials.
apparently they haven't yet figured out that good trial results makes investor relations less time consuming and dilutive...
but they don't seem to mind spending a great deal of their time providing information to message board posters...can there be any doubt as to why this stock is languishing?